MARKET

ATHA

ATHA

Athira Pharma, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.77
-0.53
-5.15%
Closed 19:44 07/29 EDT
OPEN
10.39
PREV CLOSE
10.30
HIGH
10.41
LOW
9.68
VOLUME
565.90K
TURNOVER
--
52 WEEK HIGH
34.79
52 WEEK LOW
9.22
MARKET CAP
281.52M
P/E (TTM)
-5.0036
1D
5D
1M
3M
1Y
5Y
Lindbrook Capital, LLC Buys The Walt Disney Co, Novus Capital Corp II, SPDR Gold Shares ETF, ...
GuruFocus News · 2d ago
Athira Pharma, Inc. (ATHA) Stock Sinks As Market Gains: What You Should Know
Zacks.com · 3d ago
Athira Deadline Alert
New York, New York--(Newsfile Corp. - July 26, 2021) -  Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA) and reminds investors of the Augu...
Newsfile Corp · 3d ago
ATHIRA DEADLINE ALERT: Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their Options
NEW YORK, July 25, 2021 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Athira Pharma, Inc. (“Athira” or the “Company”) (NASDAQ:ATHA) and reminds investors of the August 24, 2021 d...
GlobeNewswire · 4d ago
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start to the pharma reporting season.
Benzinga · 4d ago
Kessler Topaz Meltzer & Check, LLP: Final Deadline Reminder for Athira Pharma, Inc. Investors - ATHA
The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that securities fraud class action lawsuits have been filed in the United States District Court for the Western District of Washington against Athira Pharma, Inc. (NASDAQ: ATHA) ("Athira"...
GlobeNewswire · 6d ago
Athira Update
New York, New York--(Newsfile Corp. - July 22, 2021) -  Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA) and reminds investors of the Augu...
Newsfile Corp · 07/23 00:39
Bristlecone Advisors, LLC Buys Athira Pharma Inc, Palantir Technologies Inc, BTC BlackRock ...
GuruFocus News · 07/21 16:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATHA. Analyze the recent business situations of Athira Pharma, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATHA stock price target is 41.50 with a high estimate of 51.00 and a low estimate of 36.00.
EPS
Institutional Holdings
Institutions: 68
Institutional Holdings: 26.32M
% Owned: 91.34%
Shares Outstanding: 28.81M
TypeInstitutionsShares
Increased
27
4.04M
New
10
1.53M
Decreased
15
491.72K
Sold Out
13
290.14K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Non-Executive Chairman/Independent Director
Tadataka Yamada
President/Chief Executive Officer/Director
Leen Kawas
Chief Financial Officer/Secretary
Glenna Mileson
Chief Operating Officer
Mark Litton
Chief Technology Officer
Rachel Lenington
Vice President
Kevin Church
Other
Hans Moebius
Independent Director
Joseph Edelman
Independent Director
John Fluke
Independent Director
James Johnson
Independent Director
Barbara Kosacz
Independent Director
Kelly Romano
No Data
About ATHA
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company’s pipeline is built from its drug discovery platform (ATH) platform, and consists of a series of small molecules that are designed to target either the central nervous system (CNS), by crossing the blood brain barrier (BBB), or the peripheral nervous system. The ATH platform utilizes proprietary technology to target and enhance the activity of a vital neuronal growth factor that promotes neuronal health and regeneration. The Company is developing ATH-1017, for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer’s disease (AD). ATH-1017 is designed to enhance neuronal health and promote regeneration, thereby improving symptoms in cognitively impaired subjects.

Webull offers kinds of Athira Pharma Inc stock information, including NASDAQ:ATHA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATHA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATHA stock methods without spending real money on the virtual paper trading platform.